Insulin pump coverage criteria
This article was originally published in The Gray Sheet
Executive Summary
Review of Medtronic MiniMed's April 1 request that CMS remove the C-peptide testing requirement from insulin pump national coverage criteria will be complete by Oct. 1. The American Association of Clinical Endocrinologists and other opinion leaders plan to send letters supporting the change. CMS maintains that C-peptide level assesses "residual beta-cell function by measuring insulin secretory ability and ensuring appropriateness of the infusion pump"...
You may also be interested in...
Caregivers Weigh In On CMS Insulin Pump Coverage: C-peptide Test Must Go
CMS should eliminate its requirement that all patients seeking coverage for insulin pumps demonstrate abnormally low C-peptide levels, according to the American Association of Clinical Endocrinologists
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.